Focused On-demand Library for POU domain, class 3, transcription factor 3

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

P20264

UPID:

PO3F3_HUMAN

Alternative names:

Brain-specific homeobox/POU domain protein 1; Octamer-binding protein 8; Octamer-binding transcription factor 8

Alternative UPACC:

P20264; P78379; Q4ZG25

Background:

POU domain, class 3, transcription factor 3 (POU3F3), also known as Brain-specific homeobox/POU domain protein 1, Octamer-binding protein 8, and Octamer-binding transcription factor 8, plays a pivotal role in neuronal development. It acts synergistically with SOX11 and SOX4, and is implicated in enhancer activity at the embryonic met-mesencephalic junction, recognizing the octamer motif.

Therapeutic significance:

POU3F3 is linked to Snijders Blok-Fisher syndrome, a neurodevelopmental disorder with symptoms including developmental delay, hypotonia, and intellectual disability. Understanding the role of POU3F3 could open doors to potential therapeutic strategies for this syndrome.